Nicardipine in Models of Myocardial Infarction

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1985 Jan 1

PMID 4027150

Citations 3

Authors

B J Alps

C Calder

A Wilson

Affiliations

Soon will be listed here.

Abstract

In a dog model of partial myocardial ischaemia, superimposed ST segment elevations in epicardial ECGs were inhibited by nicardipine over a cumulative i.v. dose range of 1-20 micrograms kg-1. Over the cumulative i.v. dose range of 0.5-166.5 micrograms kg-1, nicardipine had little overall effect on gross cardiac conduction, at spontaneous heart rate. Dogs that received oral 1-2 mg kg-1 nicardipine daily for 16 weeks and then survived 1 week occlusion of the left anterior descending coronary artery (LAD) developed a superior coronary collateral circulation compared with untreated animals. Nicardipine given by three different dosing schedules to baboons markedly limited myocardial infarction over a 6 h period of LAD occlusion. Compared with a group of completely untreated dogs, there was protection of the myocardium in the animals given nicardipine that survived 3 months occlusion of the LAD.

Citing Articles

'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Freedman D, Waters D Drugs. 1987; 34(5):578-98.

PMID: 3319491 DOI: 10.2165/00003495-198734050-00005.

Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Sorkin E, Clissold S Drugs. 1987; 33(4):296-345.

PMID: 3297616 DOI: 10.2165/00003495-198733040-00002.

A comparison of the effects of a series of anti-anginal agents in a novel canine model of transient myocardial ischaemia.

Allely M, Alps B Br J Pharmacol. 1989; 96(4):977-85.

PMID: 2743088 PMC: 1854441. DOI: 10.1111/j.1476-5381.1989.tb11910.x.

References

SCHAPER W, XHONNEUX R, Jageneau A . Stimulation of the coronary collateral circulation by lidoflazine (R 7904). Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1965; 252(1):1-8. DOI: 10.1007/BF00246424. View

NAYLER W . Calcium antagonists. Eur Heart J. 1980; 1(3):225-37. DOI: 10.1093/oxfordjournals.eurheartj.a061123. View

Reid D, Pelides L, Shillingford J . Surface mapping of RS-T segment in acute myocardial infarction. Br Heart J. 1971; 33(3):370-4. PMC: 458420. DOI: 10.1136/hrt.33.3.370. View

Baum T, Rowles G, Shropshire A . Antiarrhythmic actions of two new beta adrenergic blocking agents, Kö 1313 and Kö 1366. J Pharmacol Exp Ther. 1971; 176(2):350-60. View

Lubbe W, Peisach M, Pretorius R, Bruyneel K, Opie L . Distribution of myocardial blood flow before and after coronary artery ligation in the baboon. Relation to early ventricular fibrillation. Cardiovasc Res. 1974; 8(4):478-87. DOI: 10.1093/cvr/8.4.478. View

Smith H, Singh B, Nisbet H, Norris R . Effects of verapamil on infarct size following experimental coronary occlusion. Cardiovasc Res. 1975; 9(4):569-78. DOI: 10.1093/cvr/9.4.569. View

Szekeres L, Csik V, Udvary E . Nitroglycerin and dipyridamole on cardiac metabolism and dynamics in a new experimental model of angina pectoris. J Pharmacol Exp Ther. 1976; 196(1):15-28. View

Hillis L, Askenazi J, Braunwald E, Radvany P, Muller J, Fishbein M . Use of changes in the epicardial QRS complex to assess interventions which modify the extent of myocardial necrosis following coronary artery occlusion. Circulation. 1976; 54(4):591-8. DOI: 10.1161/01.cir.54.4.591. View

Reimer K, Lowe J, Jennings R . Effect of the calcium antagonist verapamil on necrosis following temporary coronary artery occlusion in dogs. Circulation. 1977; 55(4):581-7. DOI: 10.1161/01.cir.55.4.581. View

10.

Takenaka T, Usuda S, Nomura T, Maeno H, Sado T . Vasodilator profile of a new 1,4-dihydropyridine derivative, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-[2-(N-benzyl-N-methylamino)]-ethyl ester 5-methyl ester hydrochloride (YC-93). Arzneimittelforschung. 1976; 26(12):2172-8. View

11.

Grinwald P, NAYLER W . Calcium entry in the calcium paradox. J Mol Cell Cardiol. 1981; 13(10):867-80. DOI: 10.1016/0022-2828(81)90286-8. View

12.

Geary G, Smith G, Suehiro G, McNamara J . Failure of nifedipine therapy to reduce myocardial infarct size in the baboon. Am J Cardiol. 1982; 49(2):331-8. DOI: 10.1016/0002-9149(82)90509-4. View

13.

Nakaya H, Kanno M . Effects of nicardipine, a new dihydropyridine vasodilator, on coronary circulation and ischemia-induced conduction delay in dogs. Arzneimittelforschung. 1982; 32(6):626-9. View

14.

Chambers D, Yellon D, Hearse D, Downey J . Effects of flurbiprofen in altering the size of myocardial infarcts in dogs: reduction or delay?. Am J Cardiol. 1983; 51(5):884-90. DOI: 10.1016/s0002-9149(83)80149-0. View

15.

Csik V, Szekeres L, Udvary E . Comparison of two calcium antagonists, verapamil and fendiline, in an experimental model of myocardial ischaemia mimicking classical angina on effort. Br J Pharmacol. 1983; 79(1):37-43. PMC: 2044837. DOI: 10.1111/j.1476-5381.1983.tb10492.x. View

16.

Alps B, Calder C, Wilson A . The beneficial effect of nicardipine compared with nifedipine and verapamil in limiting myocardial infarct size in baboons. Arzneimittelforschung. 1983; 33(6):868-76. View

17.

Alps B, Calder C, Wilson A . The beneficial effect of nicardipine on the healing of myocardial infarcts in dogs. Arzneimittelforschung. 1983; 33(12):1638-46. View

18.

MEESMANN W, Busch G, BRAASCH W, BACHMANN G . [DEVELOPMENT OF CORONARY COLLATERAL CIRCULATION BY CHRONIC ORAL PERSANTIN THERAPY]. Med Welt. 1964; 20:1106-11. View

19.

Higuchi S, Sasaki H, SHIOBARA Y, Sado T . Absorption, excretion and metabolism of a new dihydropyridine diester cerebral vasodilator in rats and dogs. Xenobiotica. 1977; 7(8):469-79. DOI: 10.3109/00498257709035806. View

20.

Henry P, Schuchleib R, Davis J, Weiss E, Sobel B . Myocardial contracture and accumulation of mitochondrial calcium in ischemic rabbit heart. Am J Physiol. 1977; 233(6):H677-84. DOI: 10.1152/ajpheart.1977.233.6.H677. View